Tedizolid [856866-72-3]
Katalog-Nummer A3863-5mg
Size : 5mg
Marke : APExBIO Technology
Contact local distributor :
Telefonnummer : +1 850 650 7790
Tedizolid
Tedizolid is an oxazolidinone antimicrobial agent with MIC50 value of 0.5 μg/ml for MSSA, MRSA, VR E. faecium and VR E. faecalis and 0.25 μg/ml for MSSE, MRSE, PSSP and PRSP [1].
The resistant Gram-positive infection is a serious global health problem. For instant, the methicillin-resistant S. aureus (MRSA) has spread all over the world with rates ranging from 18 to 26 cases among 100,000 people. Besides that, there come out a serious of resistant strains such as the linezolid-resistant S. aureus (LRSA) and the vancomycin-resistant S. aureus (VRSA). Due to the unfavorable outcomes of the existed antibiotics, alternative treatments have been developed. Tedizolid is a synthetic antibiotic that works based on the inhibition of protein synthesis. It binds to the 50S ribosome and inhibits the formation of the 70S complex [1].
Tedizolid showed potent bacteriostatic activity against many resistant Gram-positive pathogens such as MSSA, MRSA, S. pyogenes and S. pneumoniae. For the enterococcal and staphylococcal isolates, tedizolid displayed more than 4-fold higher potency than that of linezolid. It also showed inhibitory effects on a panel of 169 linezolid-resistant staphylococcal isolates with 79.2% inhibition at concentration of ≤ 4μg/ml. The MIC values of tedizolid against linezolid-resistant staphylococci were in a range from 0.06 to 16 mg/L. Besides that, tedizolid was found to be the inhibitors of human monoamine oxidase with IC50 values of 8.7 and 5.7 μM for MAO-A and MAO-B, respectively [1, 2 and 3].
When treated in vivo, tedizolid was the active moiety converted from the pro-drug tedizolid phosphate. It was found that granulocytes could affect the antistaphylococcal effect of tedizolid. In neutropenic mice, the administration of tedizolid for 24 hours or 48 hours caused ED50 values of 25.2 and 35.7 mg/kg/day, respectively [1 and 4].
References:
[1] Kanafani Z A, Corey G R. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert opinion on investigational drugs, 2012, 21(4): 515-522.
[2] Rodríguez-Avial I, Culebras E, Betriu C, et al. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. Journal of antimicrobial chemotherapy, 2012, 67(1): 167-169.
[3] Flanagan S, Bartizal K, Minassian S L, et al. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrobial agents and chemotherapy, 2013, 57(7): 3060-3066.
[4] Louie A, Liu W, Kulawy R, et al. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrobial agents and chemotherapy, 2011, 55(7): 3453-3460.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 370.34 |
| Cas No. | 856866-72-3 |
| Formula | C17H15FN6O3 |
| Synonyms | TR-700; DA-7157; Torezolid; TR 700; DA 7157 |
| Solubility | insoluble in EtOH; insoluble in H2O; ≥9.25 mg/mL in DMSO with gentle warming |
| Chemical Name | (5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one |
| SDF | Download SDF |
| Canonical SMILES | CN1N=C(N=N1)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4CC(OC4=O)CO)F |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
| Cell lines | PRSP (penicillin G MICs≥2 μg/ml) clinical isolates |
| Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
| Reaction Conditions | 20h; MIC90=0.25 μM |
| Applications | Agar dilution experiments demonstrated that all 28 clinical isolates of PRSP were inhibited by tedizolid at 0.25 μg/ml (MIC range, 0.125 to 0.25 μg/ml) and all were inhibited by linezolid at 1μg/ml (MIC range, 0.125 to 1 μg/ml). Tedizolid was 4-fold more potent than linezolid against PRSP; MIC90s were 0.25 μg/ml with tedizolid and 1 μg/ml with linezolid. |
| Animal experiment [1]: | |
| Animal models | Male ICR mice |
| Dosage form | 10 mg/kg (QD); intraperitoneal inoculation |
| Applications | The majority (80%) of the untreated control mice infected with PSSP type III succumbed to the infection within 7 days. For infected mice receiving 48 h treatment with tedizolid phosphate at 2.5 mg/kg QD and 5 mg/kg QD (total daily doses, 2.5 mg/kg and 5 mg/kg, respectively), the 15-day cumulative survival rates were 50% and 80%, respectively. A 100% survival rate was achieved with tedizolid phosphate at a minimum total daily dose of 10 mg/kg (QD), which was 4-fold lower than the 40-mg/kg total daily dose of linezolid (BID) needed to obtain 100% survival. On the basis of the ED50 values in the murine pneumococcal pneumonia model, tedizolid phosphate was nearly 3-fold more potent than linezolid, with ED50s of 2.80 mg/kg/day (95% CI, 1.41 to 4.44) versus 8.09 mg/kg/day (95% CI, 4.74 to 11.91) |
| Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| References: [1] Choi S, Im W, Bartizal K. Activity of Tedizolid Phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive streptococcus pneumoniae[J]. Antimicrobial agents and chemotherapy, 2012, 56(9): 4713-4717. | |
| Description | Torezolid (also known as TR-701 and now tedizolid) is an oxazolidinone antibiotic drug. | |||||
| Targets | ||||||
| IC50 | ||||||